We demonstrate that intra-tumoural injection of Complete Freund's Adjuvant can result in a potent anti-tumour immune response.
In order to test the efficacy of this treatment, we have initiated pre-clinical trials in three species: mice, dogs and horses. Efficacy has been demonstrated in a range of solid tumours, including mastocytoma, mammary tumours and melanoma. Complete tumour regressions have been observed in all three species. Evidence of systemic immune responses (regression of non-injected metastases) have also been observed. We characterise the immune cells infiltrating mouse tumours after treatment. Finally we provide case reports on the treatment of three human cancer patients (suffering from lung or breast cancer) with intra-tumoural Complete Freund's Adjuvant.
Taken together, our data demonstrate that our treatment has major anti-tumour effects in a proportion of treated animals, and is safe for use in human cancer patients. Further trials in human cancer patients are therefore strongly warranted. Our novel treatment provides a simple and inexpensive cancer immunotherapy, applicable to a wide range of solid tumours, and of potential benefit to cancer patients around the world, including patients from developing countries.